Conference Call to Be Held December 26, 2006
MOUNTAIN VIEW, Calif., Dec. 21 /PRNewswire-FirstCall/ -- IRIDEX Corporation (Nasdaq: IRIX) announced that it anticipates filing Friday, December 22, 2006, an amended Quarterly Report on Form 10-Q/A for the first quarter of 2006 ended April 1, 2006 as well as its Quarterly Reports on Form 10-Q for the second and third quarters of 2006, ended July 1, 2006 and September 30, 2006, respectively, with the Securities and Exchange Commission (SEC). With these filings, the Company will once again be current on its filings with the SEC.
Due to management's schedules, the Company will issue a press release before the market opens on Tuesday, December 26, 2006 and will host a conference call with the investment community at 1:30 p.m. PST to discuss the results of the quarter and other developments in its business.
Interested parties may access the live conference call via telephone by dialing 800-257-1836 (US) or 303-262-2138 (International), or visit the Company's website at www.iridex.com. A telephone replay will be available beginning on Tuesday, December 26, 2006 through Tuesday, January 2, 2007 by dialing 800-405-2236 (US) or 303-590-3000 (International) and entering Passcode 11079849#.
About IRIDEX
IRIDEX Corporation is a leading worldwide provider of therapeutic based laser systems, disposable laser probes and delivery devices to treat eye diseases in ophthalmology and skin diseases in dermatology markets (also referred to as aesthetics). IRIDEX products are sold in the United States through a direct sales force and internationally through a network of 77 independent distributors into 107 countries. For further information, visit the Company's website at www.iridex.com.
Safe Harbor Statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Act of 1934, as amended, relating to the filing of our amended Quarterly Report on Form 10-Q/A for the first quarter of 2006 and our Quarterly Reports on Form 10-Q for the second and third quarters of 2006. Such forward-looking statements are based on current expectations, management's beliefs, and certain assumptions made by management, and there can be no assurance concerning the timing for the filing of our amended Quarterly Report on Form 10-Q/A for the first quarter of 2006 or our Quarterly Reports on Form 10-Q for the second and third quarters of 2006. Actual timing and ability to file these Quarterly Reports may differ materially. Additional risks and uncertainties to which the Company is subject may include, but may not necessarily be limited to, the amount of orders that the Company receives and ships, dependence on international sales and the Company's network of independent distributors, the risks associated with bringing new products to market, and the results of clinical trials and competition in our markets, as well as the risks associated with a competitive market for management talent and the risks inherent with identifying, negotiating and integrating strategic acquisitions of complementary businesses, products or technologies. Please see a detailed description of these risks contained in our Quarterly Reports on Form 10-Q and Annual Report on Form 10-K for the fiscal year ended December 31, 2005 filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated.
SOURCE IRIDEX Corporation
12/21/2006
CONTACT: Larry Tannenbaum, Chief Financial Officer of IRIDEX
Corporation, +1-650-940-4700
Web site: http://www.iridex.com
